TIE2-expressing monocytes: A novel cellular biomarker for hepatocellular carcinoma?

Hepatology

Volumn 57, Issue 4, 2013, Pages 1294-1296

  De Palma, Michele ^a   Coukos, George ^b   Semela, David ^c,d  

^a EPFL   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANGIOPOIETIN RECEPTOR; CD133 ANTIGEN; SORAFENIB; VASCULOTROPIN RECEPTOR 2;

ALCOHOL LIVER CIRRHOSIS; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; EDITORIAL; ENDOTHELIAL PROGENITOR CELL; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; MONOCYTE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECURRENCE RISK; SYMPTOMATOLOGY;

CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MONOCYTES; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, TIE-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84876107099     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26025     Document Type: Editorial

References (20)

1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127.
2. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. HEPATOLOGY 2011; 53: 1020-1022.
3. Matsubara T, Kanto T, Kuroda S, Yoshio S, Higashitani K, Kakita N, et al. TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlated with angiogenesis. HEPATOLOGY 2012 57: 1416-1425.
4. Ho JW, Pang RW, Lau C, Sun CK, Yu WC, Fan ST, Poon RT. Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. HEPATOLOGY 2006; 44: 836-843.
5. Shao YY, Lin ZZ, Chen TJ, Hsu C, Shen YC, Hsu CH, Cheng AL. High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy. Oncology 2011; 81: 98-103.
6. Case J, Mead LE, Bessler WK, Prater D, White HA, Saadatzadeh MR, et al. Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol 2007; 35: 1109-1118.
7. Motz GT, Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol 2011; 11: 702-711.
8. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, Manns MP, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008; 135: 234-243.
9. Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H, et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. HEPATOLOGY 2009; 50: 799-807.
10. Fernandez M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol 2009; 50: 604-620.
11. Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol 2004; 41: 864-880.
12. De Palma M, Naldini L. Role of haematopoietic cells and endothelial progenitors in tumour angiogenesis. Biochim Biophys Acta 2006; 1766: 159-166.
13. De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M, Naldini L. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005; 8: 211-226.
14. Venneri MA, De Palma M, Ponzoni M, Pucci F, Scielzo C, Zonari E, et al. Identification of proangiogenic TIE2- expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 2007; 109: 5276-5285.
15. Murdoch C, Tazzyman S, Webster S, Lewis CE. Expression of Tie-2 by human monocytes and their responses to angiopoietin-2. J Immunol 2007; 178: 7405-7411.
16. Hristov M, Schmitz S, Schuhmann C, Leyendecker T, von Hundelshausen P, Krotz F, et al. An optimized flow cytometry protocol for analysis of angiogenic monocytes and endothelial progenitor cells in peripheral blood. Cytometry A 2009; 75: 848-853.
17. Goede V, Coutelle O, Shimabukuro-Vornhagen A, Holtick U, Neuneier J, Koslowsky TC, et al. Analysis of Tie2-expressing monocytes (TEM) in patients with colorectal cancer. Cancer Invest 2012; 30: 225-230.
18. Rodriguez-Munoz Y, Martin-Vilchez S, Lopez-Rodriguez R, Hernandez-Bartolome A, Trapero-Marugan M, Borque MJ, et al. Peripheral blood monocyte subsets predict antiviral response in chronic hepatitis C. Aliment Pharmacol Ther 2011; 34: 960-971.
19. Llovet JM, Pena CE, Lathia CD, Shan M, Meinhardt G, Bruix J. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18: 2290-2300.
20. Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011; 19: 512-526.